Press release
Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Discover the latest drugs and treatment options in the Prurigo Nodularis Pipeline. Dive into DelveInsight's comprehensive report today! @ Prurigo Nodularis Pipeline Outlook [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Prurigo Nodularis Marketed and Pipeline Drugs Report
* In May 2025, Incyte Corporation announced a study to evaluate the effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
* In May 2025, Amgen conducted a phase 3 study to assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects with Prurigo Nodularis Who Are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies.
* DelveInsight's Prurigo Nodularis Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Prurigo Nodularis treatment.
* The leading Prurigo Nodularis Companies such as Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho, and others.
* Promising Prurigo Nodularis Pipeline Therapies such as Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
Stay ahead with the most recent pipeline outlook for Prurigo Nodularis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Prurigo Nodularis Treatment Drugs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prurigo Nodularis Emerging Drugs Profile
* Nemolizumab: Chugai/Galderma
Nemolizumab was discovered by Chugai, and uses Chugai's proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in blood. IL-31 has been identified as a pruritogenic cytokine, and reported to be associated with pruritus in many diseases including atopic dermatitis and hemodialysis. Nemolizumab is designed to inhibit the activities of IL-31 by competitively blocking binding with its receptor. It is currently in phase III stage of development.
* Nalbuphine ER: Trevi Therapeutics
Trevi is developing nalbuphine ER in a range of indications for which patients have few treatment options. With its dual mechanism of action, acting as both an antagonist (blocker) to the mu opioid receptor and as an agonist (activator) to the kappa opioid receptor, Nalbuphine ER has the potential to significantly improve the quality of life of patients suffering from serious neurologically mediated conditions by targeting the central and peripheral nervous systems. It is currently in phase III stage of development.
* Vixarelimab: Kiniksa Pharmaceuticals
Vixarelimab is Monoclonal antibody inhibiting signaling through oncostatin M receptor beta (OSMR). Vixarelimab inhibits signaling of interleukin-31 (IL-31) and oncostatin M (OSM), 2 key cytokines implicated in inflammation, pruritus, and fibrosis. It is currently in phase II stage of development.
The Prurigo Nodularis Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Prurigo Nodularis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis Treatment.
* Prurigo Nodularis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Prurigo Nodularis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement,s and financing details for future advancement of the Prurigo Nodularis market
Explore groundbreaking therapies and clinical trials in the Prurigo Nodularis Pipeline. Access DelveInsight's detailed report now! @ New Prurigo Nodularis Drugs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Prurigo Nodularis Companies
Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Infusion
* Intradermal
* Intramuscular
* Intranasal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Molecule Type
Prurigo Nodularis Products have been categorized under various Molecule types such as
* Gene therapies
* Small molecule
* Vaccines
* Polymers
* Peptides
* Monoclonal antibodies
* Product Type
Unveil the future of Prurigo Nodularis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Prurigo Nodularis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Prurigo Nodularis Pipeline Report
* Coverage- Global
* Prurigo Nodularis Companies- Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho and others.
* Promising Prurigo Nodularis Pipeline Therapies- Nalbuphine HCl ER, Povorcitinib, Upadacitinib, Ruxolitinib Cream, INCB054707, Barzolvolimab, Nemolizumab and others.
* Prurigo Nodularis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Prurigo Nodularis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Prurigo Nodularis Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Prurigo Nodularis Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Prurigo Nodularis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Prurigo Nodularis - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Prurigo Nodularis Collaboration Deals
* Late Stage Products (Phase III)
* Nemolizumab: Chugai/Galderma
* Nalbuphine ER: Trevi Therapeutics
* Mid Stage Products (Phase II)
* Vixarelimab: Kiniksa Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Pre-clinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Prurigo Nodularis Key Companies
* Prurigo Nodularis Key Products
* Prurigo Nodularis- Unmet Needs
* Prurigo Nodularis- Market Drivers and Barriers
* Prurigo Nodularis- Future Perspectives and Conclusion
* Prurigo Nodularis Analyst Views
* Prurigo Nodularis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=prurigo-nodularis-pipeline-appears-robust-with-5-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prurigo Nodularis Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4024328 • Views: …
More Releases from ABNewswire
Spinocerebellar Ataxias Pipeline 2025: Key Companies, MOA, ROA, and Clinical Tri …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/spinocerebellar-ataxias-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar Ataxias Pipeline report…
Top 7 Deployment Strategies for Maximizing ROI with the Anno AI Robot Coffee Mac …
The retail landscape is undergoing a dramatic transformation, driven by soaring labor costs and the consumer demand for instant gratification. In this new era, the traditional brick-and-mortar coffee shop model is increasingly inefficient. The solution lies in smart automation, and the AI robot coffee machine is leading the charge.
As a China top manufacturer of commercial unmanned retail solutions, Anno Robot has engineered its systems not just for performance (boasting 98%…
Las Vegas Fashion Show: Analysis of North American Buyers' Purchasing Habits
The MAGIC SHOW in Las Vegas: An Analysis of North American Buyers' Purchasing Habits
As a bellwether for the global apparel industry, the MAGIC SHOW in Las Vegas is not only a showcase for the latest designs but also a central hub connecting suppliers with professional North American buyers. For independent sellers focused on exporting men's jackets [https://www.hzwincome.com/zd-contrasting-color-green-bomber-jacket/], understanding the purchasing habits of North American buyers at the show is the…
Lower Explosive Limit not equal to Alarm Value: 3 Major Pitfalls in Combustible …
Gas Detection Safety Essentials: From Concentration Units to 4-in-1 Detection
During confined space operations, a worker entered without testing the oxygen concentration and fainted due to hypoxia. In a chemical plant, a combustible gas alarm falsely triggered because the unit was mistakenly set to mg/m instead of ppm... These real cases highlight a core issue: a lack of knowledge in gas detection can directly lead to safety accidents.
As a safety manager…
More Releases for Prurigo
Prurigo Nodularis Market Growth, Applications, Innovations and Business Outlook …
Introduction
Prurigo nodularis (PN) is a rare, chronic inflammatory skin disease characterized by intensely itchy nodules that severely impair quality of life. The exact cause remains unclear, but PN is linked to immune dysregulation, chronic pruritus pathways, and systemic diseases such as atopic dermatitis, diabetes, and liver disorders. For decades, management relied on corticosteroids, antihistamines, and immunosuppressants, with limited efficacy and safety concerns in long-term use.
The landscape has changed dramatically with…
Prurigo Nodularis Treatment Market Opportunities & Challenges, Novel Therapies T …
The Global Prurigo Nodularis Treatment Market reached USD 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2031. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2024-2031.
Prurigo Nodularis Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to…
Prurigo Nodularis Pipeline: Emerging Therapies Set to Reshape the Prurigo Nodula …
The treatment landscape of Prurigo Nodularis (PN), a chronic, intensely pruritic skin disorder, is undergoing a dynamic transformation, fueled by a growing pipeline of novel therapeutics from leading pharma and biotech companies. Notable players such as Menlo Therapeutics, Galderma R&D, and Kiniksa Pharmaceuticals are driving innovation with therapies targeting underlying immune dysregulation, including IL-31 and JAK/STAT pathways, central to PN pathogenesis. These emerging drugs aim to address the high unmet…
Prurigo Nodularis Treatment Market Current Status and Future Prospects till 2031
Prurigo Nodularis (PN) is a chronic dermatologic condition marked by intense itching and the development of nodules on the skin. The Prurigo Nodularis Treatment Market focuses on therapeutic interventions to alleviate symptoms and provide relief to patients suffering from this condition. Treatments include topical corticosteroids, immunosuppressants, and biologic therapies. The current market value of Prurigo Nodularis treatment is driven by the increasing awareness of PN and advancements in treatment options.…
Prurigo Nodularis Treatment Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Prurigo Nodularis Treatment Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.
Market Overview for Prurigo Nodularis Treatment Market
Prurigo Nodularis Treatment Market OverviewPrurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules or papules that can significantly impair quality of…
Prurigo nodularis Market: F: Information, Figures and Analytical Insights 2021-2 …
The Prurigo nodularis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the…
